WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced a significant leadership change as Craig Fraser steps down from his role as Chief Executive Officer, effective December 1, 2024. After nearly nine years of dedicated service, Fraser will transition to the role of Chairman of the Board of Directors. The company has appointed Jed Latkin, a current director, as the new CEO, while he continues his role on the board.
Craig Fraser, who began his tenure as CEO in January 2016, has spearheaded numerous clinical studies and guided the company through an uplisting to Nasdaq among other strategic moves, establishing Windtree as a late-stage cardiovascular-focused company. Reflecting on his decision, Fraser stated, “In planning a transition, the question of timing as well as a successor has always been a key consideration for me. The Company is in a good place with its lead program and having someone as experienced and strong as Jed, who also knows the team and program and is a talented dealmaker, is ideal.” Fraser expressed his commitment to ensuring a seamless transition and looks forward to continuing his contributions from the board.
Jed Latkin brings to Windtree nearly 30 years of experience in finance and biotechnology. His previous roles include CEO of Navidea Biopharmaceuticals, where he successfully executed strategic deals and raised significant capital. He also held leadership positions at ProPhase Labs and Black Elk Energy Offshore, building a robust background in investment banking and strategic operations.
Expressing enthusiasm for his new role, Latkin said, “I am excited to be joining Windtree full time as its CEO to create value and lead the company into the next stage of growth and progress. Istaroxime and the SERCA2a activator platform have delivered compelling clinical and preclinical results and represent a significant opportunity to create value and be important new therapies.” Latkin is optimistic about the potential of Windtree’s pipeline, which includes promising developments in oncology, and is eager to capitalize on these opportunities with the experienced team at Windtree.
This leadership transition marks a pivotal moment for Windtree Therapeutics as it gears up for future growth and innovation in the pharmaceutical landscape.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.